SECOND REGULAR SESSION HOUSE BILL NO. 1366

98TH GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE HUBRECHT.

D. ADAM CRUMBLISS, Chief Clerk

AN ACT

To repeal sections 338.056, 338.059, and 338.100, RSMo, and to enact in lieu thereof four new sections relating to interchangeable biological products.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Sections 338.056, 338.059, and 338.100, RSMo, are repealed and four new

2 sections enacted in lieu thereof, to be known as sections 338.056, 338.059, 338.085, and
3 338.100, to read as follows:

338.056. 1. Except as provided in subsection 2 of this section, the pharmacist filling 2 prescription orders for drug products prescribed by trade or brand name may select another drug product with the same active chemical ingredients of the same strength, quantity and dosage 3 form, and of the same generic drug type, as determined by the United States Adopted Names and 4 accepted by the Federal Food and Drug Administration. Selection pursuant to this section is 5 within the discretion of the pharmacist, except as provided in subsection 2 of this section. The 6 pharmacist who selects the drug or interchangeable biological product to be dispensed pursuant 7 to this section shall assume the same responsibility for selecting the dispensed drug or biological 8 9 product as would be incurred in filling a prescription for a drug or interchangeable biological product prescribed by generic name. The pharmacist shall not select a drug or interchangeable 10 biological product pursuant to this section unless the product selected costs the patient less than 11 the prescribed product. 12 13 2. A pharmacist who receives a prescription for a brand name drug or biological

A pharmacist who receives a prescription for a brand name drug or biological
 product may, unless requested otherwise by the purchaser, select a less expensive generically
 equivalent or interchangeable biological product under the following circumstances:

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

4897H.01I

16 (1) If a written prescription is involved, the prescription form used shall have two 17 signature lines at opposite ends at the bottom of the form. Under the line at the right side shall 18 be clearly printed the words: "Dispense as Written". Under the line at the left side shall be clearly printed the words "Substitution Permitted". The prescriber shall communicate the 19 instructions to the pharmacist by signing the appropriate line. No prescription shall be valid 20 21 without the signature of the prescriber on one of these lines;

22

(2) If an oral prescription is involved, the practitioner or the practitioner's agent, 23 communicating the instructions to the pharmacist, shall instruct the pharmacist as to whether or 24 not a therapeutically equivalent generic drug or interchangeable biological product may be 25 substituted. The pharmacist shall note the instructions on the file copy of the prescription.

26 3. All prescriptions written in the state of Missouri by practitioners authorized to write 27 prescriptions shall be on forms which comply with subsection 2 hereof.

4. Notwithstanding the provisions of subsection 2 of this section to the contrary, a 28 29 pharmacist may fill a prescription for a brand name drug by substituting a generically equivalent

drug or interchangeable biological product when [generic] substitution is allowed in 30

31 accordance with the laws of the state where the prescribing practitioner is located.

32

5. Violations of this section are infractions.

338.059. 1. It shall be the duty of a licensed pharmacist or a physician to affix or have affixed by someone under the pharmacist's or physician's supervision a label to each and every 2 3 container provided to a consumer in which is placed any prescription drug or biological product upon which is typed or written the following information: 4

- 5
- (1) The date the prescription is filled;
- 6 (2) The sequential number or other unique identifier;
- 7 (3) The patient's name;
- 8 (4) The prescriber's directions for usage;
- 9 (5) The prescriber's name;

10 (6) The name and address of the pharmacy;

11 (7) The exact name and dosage of the drug dispensed;

12

(8) There may be one line under the information provided in subdivisions (1) to (7) of 13 this subsection stating "Refill" with a blank line or squares following or the words "No Refill";

14 (9) When a generic or interchangeable biological substitution is dispensed, the name 15 of the manufacturer or an abbreviation thereof shall appear on the label or in the pharmacist's records as required in section 338.100. 16

17 2. The label of any drug or biological product which is sold at wholesale in this state and which requires a prescription to be dispensed at retail shall contain the name of the 18 19 manufacturer, expiration date, if applicable, batch or lot number and national drug code.

338.085. 1. As used in this chapter, the following terms shall mean:

- (1) "Biological product", the same meaning as such term is defined under 42 U.S.C. 2 3 Section 262; 4 (2) "Interchangeable biological product", a biological product that the Food and 5 **Drug Administration:** (a) Has licensed and determined meets the standards for interchangeability under 6 7 42 U.S.C. Section 262(k)(4); or 8 (b) Has determined is therapeutically equivalent as set forth in the latest edition of 9 or supplement to the Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). 10 11 2. A pharmacist may substitute an interchangeable biological product for a 12 prescribed product only if all of the following conditions are met: The substituted product has been determined by the Food and Drug 13 (1) 14 Administration to be an interchangeable biological product, as defined under subsection 15 1 of this section, with the prescribed biological product; 16 (2) The substitution occurs according to the provisions of section 338.056; and 17 (3) The pharmacy informs the patient of the substitution. 18 3. Within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall make an entry of the specific 19 20 product provided to the patient including the name of the product and manufacturer. The 21 communication shall be conveyed by making an entry that can be electronically accessed 22 by the prescriber through: 23 (1) An interoperable electronic medical records system; 24 (2) An electronic prescribing technology; or 25 (3) A pharmacy record. 26 4. If an entry cannot be made under the provisions of subsection 3 of this section, 27 the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission, or other prevailing means, except that 28 29 communication shall not be required if: 30 (1) There is no Food and Drug Administration-approved interchangeable biological 31 product for the product prescribed; or 32 (2) A refill prescription is not changed from the product dispensed on the prior
- 33 filling of the prescription.

5. The pharmacist shall maintain records in a manner consistent with section
338.100.

3

36 6. The pharmacist shall label prescriptions in a manner consistent with section
37 338.059.

7. The board of pharmacy shall maintain a link on its website to the current list of
 all biological products determined by the Food and Drug Administration to be
 interchangeable with a specific biological product.

41 8. The board of pharmacy may promulgate rules for compliance with the 42 provisions of this section. Any rule or portion of a rule, as that term is defined in section 43 536.010, that is created under the authority delegated in this section shall become effective 44 only if it complies with and is subject to all of the provisions of chapter 536 and, if 45 applicable, section 536.028. This section and chapter 536 are nonseverable, and if any of 46 the powers vested with the general assembly pursuant to chapter 536 to review, to delay the effective date, or to disapprove and annul a rule are subsequently held 47 unconstitutional, then the grant of rulemaking authority and any rule proposed or adopted 48 49 after August 28, 2016, shall be invalid and void.

338.100. 1. Every permit holder of a licensed pharmacy shall cause to be kept in a uniform fashion consistent with this section a suitable book, file, or electronic record-keeping 2 system in which shall be preserved, for a period of not less than five years, the original or order 3 of each drug or biological product which has been compounded or dispensed at such pharmacy, 4 5 according to and in compliance with standards provided by the board, and shall produce the same in court or before any grand jury whenever lawfully required. A licensed pharmacy may 6 maintain its prescription file on readable microfilm for records maintained over three years. 7 After September, 1999, a licensed pharmacy may preserve prescription files on microfilm or by 8 9 electronic media storage for records maintained over three years. The pharmacist in charge shall be responsible for complying with the permit holder's record-keeping system in compliance with 10 this section. Records maintained by a pharmacy that contain medical or drug information on 11 patients or their care shall be considered as confidential and shall only be released according to 12 13 standards provided by the board. Upon request, the pharmacist in charge of such pharmacy shall furnish to the prescriber, and may furnish to the person for whom such prescription was 14 15 compounded or dispensed, a true and correct copy of the original prescription. The file of original prescriptions kept in any format in compliance with this section, and other confidential 16 17 records, as defined by law, shall at all times be open for inspection by board of pharmacy representatives. Records maintained in an electronic record-keeping system shall contain all 18 19 information otherwise required in a manual record-keeping system. Electronic records shall be 20 readily retrievable. Pharmacies may electronically maintain the original prescription or 21 prescription order for each drug or biological product and may electronically annotate any 22 change or alteration to a prescription record in the electronic record-keeping system as authorized

by law; provided however, original written and faxed prescriptions shall be physicallymaintained on file at the pharmacy under state and federal controlled substance laws.

25 2. An institutional pharmacy located in a hospital shall be responsible for maintaining 26 records of the transactions of the pharmacy as required by federal and state laws and as necessary 27 to maintain adequate control and accountability of all drugs. This shall include a system of 28 controls and records for the requisitioning and dispensing of pharmaceutical supplies where 29 applicable to patients, nursing care units and to other departments or services of the institution. 30 Inspection performed pursuant to this subsection shall be consistent with the provisions of 31 section 197.100.

32 3. "Electronic record-keeping system", as used in this section, shall mean a system, 33 including machines, methods of organization, and procedures, that provides input, storage, 34 processing, communications, output, and control functions for digitized images of original 35 prescriptions.

✓